IMRN News and Press, Immuron Limited From 07/23/20

Liquid Media (NASDAQ: YVR ) +63% . More news on: Liquid Media Group Ltd., Milestone Pharmaceuticals Inc., CymaBay Therapeutics, Inc., Stocks on the move, , Read more ...

Verb Technology Company (NASDAQ: VERB )   -25%  after pricing equity offering. More news on: Verb Technology Company, Inc., Tonix Pharmaceuticals Holding Corp., Novan, Inc., Stocks on the move, , Read more ...

Gainers:  Midatech Pharma (NASDAQ: MTP ) +229%. More news on: Midatech Pharma plc, Owens & Minor, Inc., Novan, Inc., Stocks on the move, , Read more ...

Immuron (NASDAQ: IMRN ) has announced registered direct offering of ~1.1M ADSs, each representing 40 of the Company’s ordinary shares, at $18.75/ADS. More news on: Immuron Limited, Healthcare stocks news, Read more ...

MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced that it has...

Immuron (NASDAQ: IMRN ) +114%  on potential of hyperimmune bovine antibodies in COVID-19. More news on: Immuron Limited, Midatech Pharma plc, New Age Beverages Corporation, , , Stocks on the move Read more ...

Nano cap Immuron Limited (NASDAQ: IMRN ) jumps  118%  premarket on robust volume in reaction to its announcement that IMM-124E, hyperimmune bovine antibodies used to make immune supplements Travelan and Protectyn, showed neutralizing activity against SARS-CoV-2 in cell-based as...

Immuron’s IMM-124E used to manufacture Travelan ® and Protectyn ® demonstrates antiviral activity against the COVID-19 virus in laboratory studies Immuron’s technology platform offers a potential new oral therapeutic approach to target SARS-CoV-2 in the GI Tract...

Gainers:  Immuron (NASDAQ: IMRN )   +121% . More news on: Immuron Limited, DPW Holdings, Inc., iBio, Inc., Stocks on the move, , Read more ...

Immuron (NASDAQ: IMRN )   surges 89%  premarket after the Naval Medical Research Center (NMRC)  received written FDA guidance in relation to the clinical development pathway of Company's new investigational drug being developed for the treatment of moderate to severe ca...